IL6 and Parkinson disease: CCL2, by reducing glutamate levels increased by N-methyl-d-aspartate (NMDA) and Tat protein, and IL-6, by preventing ROS and Ca2+ excitotoxicity in Parkinson’s and Huntington’s diseases, exert neuroprotective properties [32, 33].